Lumere

About Lumere

Lumere operates as a provider of evidence-based data and analytics solutions tailored for the healthcare sector. The company was established in 2012, originally named Procured Health, by co-founders Hani Elias, Eric Meizlish, and Will Danford. Hani Elias, who served as CEO, brought a rich background to the venture, holding JD and MPH degrees from Harvard University and prior experience as a consultant in McKinsey & Company's healthcare practice. His experience, coupled with his co-founders' expertise, aimed to address the challenge of unwarranted clinical variation and rising costs in healthcare.

The firm's core business revolves around providing a data-driven platform that assists healthcare organizations in making informed decisions about medical devices and pharmaceuticals. It serves hospitals, health systems, and physicians by offering robust analytics and comprehensive clinical research to guide purchasing and utilization choices. This is designed to help clients reduce expenses, eliminate unnecessary clinical variations, and improve patient outcomes by ensuring expenditures on drugs and devices are backed by clinical evidence. The business model is primarily subscription-based, granting clients like Yale New Haven Health and Stanford Health Care access to its solutions. The platform functions as a web-based system for managing new product requests and conducting reviews using unbiased literature, thereby creating transparency and collaborative decision-making between clinicians and administrators.

Lumere’s services include the Category Optimization solution, which provides physician-level analytics to identify variations in medical device selection across numerous service lines such as orthopedics and cardiology. Another key offering is the Product Introduction Management solution, a web-based tool that integrates a health system's purchasing data with clinical research and workflow management to standardize value analysis. In January 2020, Lumere was acquired by Global Healthcare Exchange (GHX) for an undisclosed amount, becoming a wholly-owned subsidiary. This strategic acquisition was intended to combine Lumere's clinical data analytics with GHX's extensive supply chain network, aiming to create a comprehensive source for managing device and drug utilization. Following the acquisition, the founders and key leadership remained with the combined organization to continue their mission. In 2022, the company expanded its offerings by launching consulting services to further help healthcare providers achieve savings and reduce clinical variation.